{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:37:38Z","timestamp":1793367458392,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Genetic Engineering and Biotechnology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jgeb.2024.100444","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T22:34:56Z","timestamp":1732142096000},"page":"100444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches"],"prefix":"10.1016","volume":"22","author":[{"given":"Dilinazi","family":"Abulaiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niluopaer","family":"Tuerxun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgeb.2024.100444_b0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.7150\/jca.83219","article-title":"Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by jiyuan oridonin A","volume":"14","author":"Xu","year":"2023","journal-title":"J Cancer"},{"key":"10.1016\/j.jgeb.2024.100444_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jgeb.2024.100444_b0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O\u2019Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jgeb.2024.100444_b0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Can Cell"},{"key":"10.1016\/j.jgeb.2024.100444_b0025","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jgeb.2024.100444_b0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Can Cell"},{"key":"10.1016\/j.jgeb.2024.100444_b0035","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jgeb.2024.100444_b0040","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3892\/ol.2020.11650","article-title":"Mutations in the BCR\u2011ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis","volume":"20","author":"Liu","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jgeb.2024.100444_b0045","first-page":"243","article-title":"Resistant mutations in CML and Ph(+)ALL - role of ponatinib","volume":"8","author":"Miller","year":"2014","journal-title":"Biologics"},{"key":"10.1016\/j.jgeb.2024.100444_b0050","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2015.168","article-title":"BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","volume":"29","author":"Hughes","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jgeb.2024.100444_b0055","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.2011.35.0934","article-title":"Sensitive Detection of BCR-ABL1 Mutations in Patients with Chronic Myeloid Leukemia after Imatinib Resistance Is Predictive of Outcome during Subsequent Therapy","volume":"29","author":"Parker","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgeb.2024.100444_b0060","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgeb.2024.100444_b0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.medcli.2012.10.028","article-title":"Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors","volume":"141","author":"Marc\u00e9","year":"2013","journal-title":"Med Clin (barc)"},{"key":"10.1016\/j.jgeb.2024.100444_b0070","doi-asserted-by":"crossref","unstructured":"Singh, D.D.; Datta, M. Chapter 8 - A Promising source of anticancer drug from fungal secondary metabolite. In New and Future Developments in Microbial Biotechnology and Bioengineering; Singh, J., Gehlot, P., Eds.; Elsevier, 2020; pp. 95\u2013101 ISBN 978-0-12-821006-2.","DOI":"10.1016\/B978-0-12-821006-2.00008-X"},{"key":"10.1016\/j.jgeb.2024.100444_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1216928","article-title":"Isolation of anticancer bioactive secondary metabolites from the sponge-derived endophytic fungi Penicillium sp. and in-silico computational docking approach","volume":"14","author":"Kaliaperumal","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jgeb.2024.100444_b0080","doi-asserted-by":"crossref","unstructured":"Contigli C, de Andrade WP, Cardoso PG et al. Metabolites from fungi: a promising source of lead compounds against cancer. In Fungi Bioactive Metabolites: Integration of Pharmaceutical Applications; Deshmukh, S.K., Takahashi, J.A., Saxena, S., Eds.; Springer Nature: Singapore, 2024; pp. 283\u2013337 ISBN 978-981-9956-96-8.","DOI":"10.1007\/978-981-99-5696-8_10"},{"key":"10.1016\/j.jgeb.2024.100444_b0085","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.semcancer.2021.03.009","article-title":"How far have we explored fungi to fight cancer?","volume":"86","author":"How","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jgeb.2024.100444_b0090","doi-asserted-by":"crossref","unstructured":"Banerjee S, Paruthy SB. Preclinical and clinical perspective on fungal metabolites and their analogs as anticancer agents \u2013 from bench to bedside. In: Fungal Metabolites; M\u00e9rillon, J.-M., Ramawat, K.G., Eds.; Springer International Publishing: Cham, 2017; pp. 669\u2013700 ISBN 978-3-319-25001-4.","DOI":"10.1007\/978-3-319-25001-4_22"},{"key":"10.1016\/j.jgeb.2024.100444_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fmars.2020.543523","article-title":"Antiproliferative role of secondary metabolites from Aspergillus unguis AG 1.1 (G) isolated from marine macroalgae Enteromorpha sp. by inducing intracellular ROS production and mitochondrial membrane potential loss leading to apoptosis","volume":"7","author":"Sajna","year":"2020","journal-title":"Front. Mar. Sci."},{"key":"10.1016\/j.jgeb.2024.100444_b0100","article-title":"In silico studies on fungal metabolite against skin cancer protein (4,5-Diarylisoxazole HSP90 chaperone)","volume":"2012","author":"Kandasamy","year":"2012","journal-title":"Int Scholar Res Not"},{"key":"10.1016\/j.jgeb.2024.100444_b0105","article-title":"In vitro and in silico anticancer evaluation of secondary metabolites from an endophytic fungus aspergillus fumigatus isolated from monarda citriodora","volume":"9","author":"Gupta","year":"2024","journal-title":"Chem Select"},{"key":"10.1016\/j.jgeb.2024.100444_b0110","doi-asserted-by":"crossref","unstructured":"MeFSAT: A curated natural product database specific to secondary metabolites of medicinal fungi. RSC Adv 2021, 11, 2596\u20132607, doi:10.1039\/d0ra10322e.","DOI":"10.1039\/D0RA10322E"},{"key":"10.1016\/j.jgeb.2024.100444_b0115","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgeb.2024.100444_b0120","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.jgeb.2024.100444_b0125","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J Comput Chem"},{"key":"10.1016\/j.jgeb.2024.100444_b0130","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1021\/acs.jcim.3c01053","article-title":"SwissParam 2023: a modern web-based tool for efficient small molecule parametrization","volume":"63","author":"Bugnon","year":"2023","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.jgeb.2024.100444_b0135","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/bioinformatics\/btl461","article-title":"Bio3d: An R package for the comparative analysis of protein structures","volume":"22","author":"Grant","year":"2006","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jgeb.2024.100444_b0140","doi-asserted-by":"crossref","DOI":"10.1063\/5.0014475","article-title":"Scalable molecular dynamics on CPU and GPU architectures with NAMD","volume":"153","author":"Phillips","year":"2020","journal-title":"J Chem Phys"},{"issue":"33\u201338","key":"10.1016\/j.jgeb.2024.100444_b0145","first-page":"27","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J Mol Graph"},{"key":"10.1016\/j.jgeb.2024.100444_b0150","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.jgeb.2024.100444_b0155","doi-asserted-by":"crossref","unstructured":"Lee K, Jang J, Seo S, Lim J, Kim WY. Drug-likeness scoring based on unsupervised learning. Chem Sci 13, 554\u2013565, doi:10.1039\/d1sc05248a.","DOI":"10.1039\/D1SC05248A"},{"key":"10.1016\/j.jgeb.2024.100444_b0160","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202200682","article-title":"Phelliribsin B: A new styrylpyrone derivative from the medicinal fungus phellinus ribis","volume":"19","author":"Ren","year":"2022","journal-title":"Chem Biodivers"},{"key":"10.1016\/j.jgeb.2024.100444_b0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.56.173","article-title":"Phellifuropyranone A: a new furopyranone compound isolated from fruit bodies of wild phellinus linteus","volume":"56","author":"Kojima","year":"2008","journal-title":"Chem Pharm Bull (tokyo)"},{"key":"10.1016\/j.jgeb.2024.100444_b0170","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1021\/np060476h","article-title":"Structures, biogenesis, and biological activities of pyrano[4,3-c]isochromen-4-one derivatives from the fungus phellinus igniarius","volume":"70","author":"Wang","year":"2007","journal-title":"J Nat Prod"},{"key":"10.1016\/j.jgeb.2024.100444_b0175","first-page":"24","article-title":"A review: the bioactivities and pharmacological applications of phellinus linteus","volume":"2019","author":"Chen","year":"1888","journal-title":"Molecules"},{"key":"10.1016\/j.jgeb.2024.100444_b0180","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1246\/bcsj.20200212","article-title":"Total synthesis and structure\u2013activity relationship studies of phelligridins C and D, and phellifuropyranone A","volume":"93","author":"Ohyoshi","year":"2020","journal-title":"Bull Chem Soc Jpn"},{"key":"10.1016\/j.jgeb.2024.100444_b0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jphs.2015.10.008","article-title":"Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells","volume":"129","author":"Wei","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jgeb.2024.100444_b0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13659-024-00452-0","article-title":"Advances on anticancer fungal metabolites: sources, chemical and biological activities in the last decade (2012\u20132023)","volume":"14","author":"Evidente","year":"2024","journal-title":"Nat. Prod. Bioprospect."},{"key":"10.1016\/j.jgeb.2024.100444_b0195","article-title":"Visualization of the relationship between fungi and cancer from the perspective of bibliometric analysis","volume":"9","author":"Xu","year":"2023","journal-title":"Heliyon"}],"container-title":["Journal of Genetic Engineering and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687157X24001471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687157X24001471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T15:49:17Z","timestamp":1734018557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687157X24001471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1687157X24001471"],"URL":"https:\/\/doi.org\/10.1016\/j.jgeb.2024.100444","relation":{},"ISSN":["1687-157X"],"issn-type":[{"value":"1687-157X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches","name":"articletitle","label":"Article Title"},{"value":"Journal of Genetic Engineering and Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgeb.2024.100444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of Academy of Scientific Research and Technology.","name":"copyright","label":"Copyright"}],"article-number":"100444"}}